ZM 306416

The Uses of ZM 306416

ZM 306416 an inhibitor of tyrosine kinase RTK signaling pathway involved in anti-cancer agents. Anti-tumor, anti-metastatic agent.

The Uses of ZM 306416

ZM-306416 is a VEGFR inhibitor, inhibiting Src, VEGFR1 and Abl with IC50 of 0.33 μM, 0.33 μM and 1.3 μM, respectively.

The Uses of ZM 306416

The major metabolite of Meropenem (M225620) - a carbapenem antibiotic - in plasma and urine. This metabolite existed as a mixture of 1-pyrroline and its 2-pyrroline isomer, and the coexistence of the two isomers at equilibrium in aqueous solutions was observed by NMR.

What are the applications of Application

ZM-306416 is a receptor tyrosine kinase inhibitor that has been shown to disrupt Flt and Flk activity

Definition

ChEBI: N-(4-chloro-2-fluorophenyl)-6,7-dimethoxy-4-quinazolinamine is a member of quinazolines.

Biological Activity

zm 306416 is a selective inhibitor of vegfr with ic50 value of 0.67μm [1]. it is also reported that zm 306416 inhibits egfr with ic50 value less than 10 nm [2].vascular endothelial growth factor receptor (vegfr) is a key element of the extracellular matrix(ecm) and plays an important role in angiogenesis cooperating with its ligand vegf. several studies have demonstrated that vegfrs expressed in liquid and solid tumor cells, such as nsclc, melanoma, prostate cancer, leukemia, mesothelioma, and breast cancer and are being regarded as a promising target in clinical [3].zm 306416 is a potent vegfr inhibitor and has a different selectivity with other reported vegfr inhibitors. using a549-egfrb cells for egfrb assay revealed that zm 306416 exhibited inhibitory activity on vegfr with ic50 value of 670 nm [1]. when tested with human thyroid follicular cells, zm 306416 treatment exhibited function on reducing vegfr2 phosphorylation and inhibiting endogenous, steady-state levels of p42/44 mapk phosphorylation [4].

References

1. antczak, c., et al., a high-content biosensor-based screen identifies cell-permeable activators and inhibitors of egfr function: implications in drug discovery. j biomol screen, 2012. 17(7): p. 885-99.2. choi kj, baik ih, ye sk et al. molecular targeted therapy for hepatocellular carcinoma: present status and future directions. biol pharm bull. 2015;38(7):986-91. 3. choi, k.j., et al., molecular targeted therapy for hepatocellular carcinoma: present status and future directions. biol pharm bull, 2015. 38(7): p. 986-91.4. susarla, r., j.c. watkinson, and m.c. eggo, regulation of human thyroid follicular cell function by inhibition of vascular endothelial growth factor receptor signalling. mol cell endocrinol, 2012. 351(2): p. 199-207.